This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
H. Lundbeck A/S
Drug Names(s): MobileTrex
Description: CH-1504 is an orally available antifolate which inhibits dihydrofolate reductase (DHFR). Antifolates are structurally related to folic acid and act as antagonists to this vitamin by inhibiting DHFR, the enzyme that converts folic acid to its active form. Folic acid is required for cell growth and tissue proliferation. Hence antifolates act against against rapidly dividing cells which are characteristic of inflammatory disease and cancer.
The L-isomer of CH-1504 is CH-4051.
Chelsea and Lundbeck
In May 2014, H. Lundbeck and Chelsea announced that the companies have entered into a definitive agreement under which Lundbeck will acquire Chelsea. Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Chelsea, whereby Chelsea stockholders will be offered an upfront payment and contingent value rights (CVRs), representing a total potential consideration of up to USD 7.94 per share, or USD 658 million (approximately DKK 3.54 billion) on a fully diluted basis. The total potential consideration represents an attractive premium of 59% over the closing price of Chelsea shares on May 7, 2014.
Consideration includes USD 6.44 per share in cash, or approximately USD 530 million (approximately DKK 2.8 billion) on a fully diluted basis, as well as CVRs that may pay up to a total of an additional USD 1.50 upon achievement of certain commercial milestones related to NORTHERA's commercial performance in the...See full deal structure in Biomedtracker
Additional information available to subscribers only: